Moureq R Alotaibi1, Amal J Fatani1, Ahmed T Almnaizel1, Mohammed M Ahmed1, Hatem M Abuohashish2, Salim S Al-Rejaie3. 1. Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. 2. Department of Biomedical Dental Sciences, College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. 3. Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia, rejaie@ksu.edu.sa.
Abstract
OBJECTIVE: Diabetic complications involve multiple pathological pathways, including hyperglycemia-induced oxidative stress and inflammation. Combination therapy is usually employed to improve treatment outcomes and to lower potential adverse effects. In this study, we evaluated the effects of antidiabetic and antihypertensive agents, glibenclamide (GLI) and losartan (LT), on diabetes mellitus (DM)-associated metabolic changes in rats. MATERIALS AND METHODS: Streptozotocin-induced diabetic animals were orally treated with GLI 5 mg/kg and/or LT 25 mg/kg for 4 weeks. Blood glucose, insulin, aspartate aminotransferase, alanine aminotransferase, urinary creatinine, and urea levels were measured. Serum, liver, and kidney values of inflammatory markers, such as interleukin-1β, tumor necrosis factor alpha, and interleukin-6 were assessed, along with lipid peroxidation products (e.g., thiobarbituric acid reactive substances), endogenous antioxidants (e.g., glutathione), as well as antioxidant enzyme activities (e.g., catalase, superoxide dismutase, and glutathione peroxidase). Finally, histological changes in liver and kidney tissues were evaluated. RESULTS: DM markedly induced systemic, hepatic, and renal inflammation and lowered antioxidant defense mechanisms. Treatment of diabetic rats with either GLI or LT significantly improved liver and kidney functions and histological structure. Moreover, both medications reduced signs of oxidative stress and inflammation in blood, liver, and kidney samples. Combining GLI and LT showed similar protective potential against systemic, hepatic, and renal oxidative stress and inflammation. CONCLUSION: Adding LT to GLI therapy revealed prospective antioxidant and anti-inflammatory action, while no synergistic or additive effects were observed.
OBJECTIVE:Diabetic complications involve multiple pathological pathways, including hyperglycemia-induced oxidative stress and inflammation. Combination therapy is usually employed to improve treatment outcomes and to lower potential adverse effects. In this study, we evaluated the effects of antidiabetic and antihypertensive agents, glibenclamide (GLI) and losartan (LT), on diabetes mellitus (DM)-associated metabolic changes in rats. MATERIALS AND METHODS:Streptozotocin-induced diabetic animals were orally treated with GLI 5 mg/kg and/or LT 25 mg/kg for 4 weeks. Blood glucose, insulin, aspartate aminotransferase, alanine aminotransferase, urinary creatinine, and urea levels were measured. Serum, liver, and kidney values of inflammatory markers, such as interleukin-1β, tumor necrosis factor alpha, and interleukin-6 were assessed, along with lipid peroxidation products (e.g., thiobarbituric acid reactive substances), endogenous antioxidants (e.g., glutathione), as well as antioxidant enzyme activities (e.g., catalase, superoxide dismutase, and glutathione peroxidase). Finally, histological changes in liver and kidney tissues were evaluated. RESULTS:DM markedly induced systemic, hepatic, and renal inflammation and lowered antioxidant defense mechanisms. Treatment of diabeticrats with either GLI or LT significantly improved liver and kidney functions and histological structure. Moreover, both medications reduced signs of oxidative stress and inflammation in blood, liver, and kidney samples. Combining GLI and LT showed similar protective potential against systemic, hepatic, and renal oxidative stress and inflammation. CONCLUSION: Adding LT to GLI therapy revealed prospective antioxidant and anti-inflammatory action, while no synergistic or additive effects were observed.
Authors: D E Martin; G S DeCherney; B E Ilson; B A Jones; S C Boike; M I Freed; D K Jorkasky Journal: J Clin Pharmacol Date: 1997-02 Impact factor: 3.126
Authors: Mohamed Mohany; Ahmed Z Alanazi; Faleh Alqahtani; Osamah M Belali; Mohammed M Ahmed; Salim S Al-Rejaie Journal: PeerJ Date: 2020-06-19 Impact factor: 2.984
Authors: Ahmed Z Alanazi; Faleh Alqahtani; Ramzi A A Mothana; Mohamed Mohany; Hatem M Abuohashish; Mohammed M Ahmed; Salim S Al-Rejaie Journal: Evid Based Complement Alternat Med Date: 2020-12-10 Impact factor: 2.629
Authors: Tarek Atia; Mohammad Zahidul Iqbal; Hassan Fathy Ahmed; Hader I Sakr; M H Abdelzaher; Deaa Fekri Morsi; Mostafa E Metawee Journal: J Evid Based Integr Med Date: 2022 Jan-Dec
Authors: Abdulaziz M S AlSaad; Fawaz Alasmari; Hatem M Abuohashish; Mohamed Mohany; Mohammed M Ahmed; Salim S Al-Rejaie Journal: Redox Rep Date: 2020-12 Impact factor: 4.412
Authors: Faleh Alqahtani; Mohamed Mohany; Abdullah F Alasmari; Ahmed Z Alanazi; Osamah M Belali; Mohammed M Ahmed; Salim S Al-Rejaie Journal: Int J Med Sci Date: 2020-10-22 Impact factor: 3.738